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Our focus has been the characterization of antibody-mediated defense mech- 
anisms against Epstein-Barr virus (EBV) ~  through the development of monoclonal 
antibodies (mAb) against EBV membrane antigens (MA). EBV has been studied 
extensively because it has a central role in the pathogenesis of infectious mono- 
nucleosis (IM), two human tumors (Burkitt's lymphoma [BL] and nasopharyngeai 
carcinoma), and the X-linked lymphoproliferative syndrome (XLP), and because 
the virus persists in certain chronically or recurrently infected states (1).  EBV 
genome-carrying lymphoblastoid cell lines are termed "producer" or "nonpro- 
ducer" cells, depending upon whether they do or do not shed infectious virus 
and spontaneously express viral capsid antigen (VCA). EBV-related antigens on 
such cells can be classed as early or late on the basis of sensitivity to inhibitors of 
viral DNA synthesis such as cytosine arabinoside or phosphonoacetic acid (PAA) 
(2, 3). Late antigens are expressed only in cells actively producing the virus, and 
frequently appear in the virion itself (4, 5). EBV induces two kinds of cell surface 
neoantigens on transformed cells. Lymphocyte-determined membrane antigen 
(LYDMA) is expressed on all  EBV-transformed cells (6),  but EBV-determined 
membrane antigens are expressed only on producer cells (7). LYDMA is defined 
with cytotoxic T  cells from patients with  IM.  In vivo,  such cytotoxic T  cells 
probably destroy the  EBV-transformed cells that  are found in  the peripheral 
blood of acute IM patients (6,  8).  On  the other hand,  MA on producer cells 
could also  be  relevant to  in  vivo immune defense against  EBV because  MA, 
which are also components of the EBV envelope (5, 9), are target antigens for 
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virus-neutralizing antibody (10),  antibody-dependent  cell-mediated cytotoxicity 
(11,  12), and complement (C)-dependent cytolysis (13).  MA appear to consist of 
at  least  four  distinct  polypeptides:  350/300,  250/200,  160/140,  and  85/80 
kilodaltons  (kD)  (5,  9,  13-19).  Our  report  describes  an  anti-MA  mAb  that 
recognizes  a  200  kD  late  MA,  and  has  no  neutralizing  activity  without  C. 
However, this mAb inhibits release of virus from P3HR-1  producer cells.  The 
mAb  thus  permits  analysis  of the  mechanism  of  EBV  release,  and  probably 
defines another mechanism for immune defense against EBV infections. 
Materials and  Methods 
Medium and Cell Lines.  RPMI  1640 medium (Gibco Laboratories, Grand Island, NY) 
with  100 t~g/ml streptomycin and  100  IU/ml penicillin was supplemented with 2% fetal 
calf serum and 8% newborn calf serum. Raji, an EBV-nonproducer BL cell line (20), was 
a target for superinfection with EBV derived from the P3HR-1 cell line (21).  CEM was a 
T  cell line (22). 
Preparation of Microsomal Membrane Immunogen.  P3HR-! cells (108) were treated with 
12-0-tetradecanoyl phorbol-13-acetate (TPA) (20 ng/ml) and n-butyrate (4 mM) for 2 d 
at  37°C  (hereafter termed  P3-T/B  cells),  and  washed  with  phosphate-buffered saline 
(PBS).  Such cells expressed high levels of MA (50-70%, in contrast to 0.1-2% for MA  + 
control P3HR-1 cells). The cell pellets were lysed in 0.01  M Tris-HCI buffer, pH 8.1, by 
vortex agitation for 1 min. This suspension was centrifuged at 600 g for 5 min. The pellet 
was reextracted, and the two supernatants from each extraction were pooled and centri- 
fuged at 110,000 g for 1 h. The resulting microsomal membrane pellet was suspended at 
~4 mg/ml by Dounce homogenization in 4 ml of 0.15 M NaCI, and was stored in aliquots 
at -70°C. 
mAb  Production.  BALB/c  mice  were  immunized  subcutaneously  in  footpads  with 
antigen emulsified in complete Freund's adjuvant, and were boosted with three intraper- 
itoneal injections of saline-suspended immunogen (0.3 ml of a  1:10  dilution) given at 3- 
wk intervals. Fusions were made according to the EMBO protocol (23).  Briefly, 4 X  107 
spleen cells and 2 ×  10 ~ SP 2/0 myeloma cells were fused in the presence of polyethylene 
glycol. The cells were distributed into 48 wells (1 ml/well) with feeder mouse thymocytes 
in Dulbecco's modified Eagle's medium (DMEM) containing hypoxanthine, aminopterin, 
thymidine, penicillin,  streptomycin, glutamine,  2-mercaptoethanol, 2% fetal calf serum, 
and 8% newborn calf serum. After 14 d of feeding in this medium, cells were transferred 
to DMEM containing hypoxanthine, thymidine, and basic supplements. Supernatants of 
these cultures were assayed for anti-MA by enzyme-linked immunosorbent assay (ELISA) 
and immunofluorescent techniques. Cloning of selected cultures was performed by limit- 
ing dilution of cells.  Ascites fluid was raised from intraperitoneal culture of hybridomas 
in pristane-primed BALB/c mice, and heat-inactivated. 
Immunofluorescence.  An indirect membrane immunofluorescence technique was used 
to assay for EBV-MA (24).  ~106 cells were pelleted, resuspended for 30 rain at 37°C in 
2 drops (-0.05 ml) of either 1:20 diluted anti-MA-reactive normal human sera 53 or 70 
(anti-MA titers  1:160),  or appropriately diluted  mAb. After washing with PBS, the cells 
were incubated at 37°C for 30 rain with two drops of fluorescein isothiocyanate (FITC)- 
labeled rabbit antibody against human IgG (gamma-specific), or F(ab')~ sheep anti-mouse 
lgG showing no crossreaction with human IgG. After washing with PBS, the cells were 
suspended in one drop of 50% glycerol in PBS.  A drop of this cell suspension was placed 
under a coverslip for examination with a fluorescence microscope. 
The indirect immunofluorescence test for intracellular antigens was carried out accord- 
ing to established procedures (25).  Early antigen (EA) was detected with a serum from a 
patient (103)  with  nasopharyngeal carcinoma (anti-EA titer  1:320).  VCA  was detected 
with two human sera, 53 or 70 (anti-VCA titer 1:160; anti-EA titer <1:10 in each case). 
Cells were washed in PBS, spotted on a glass slide, dried, and fixed in acetone for 10 rain 
at room temperature.  The fixed cells were incubated at  37°C  with  a  drop of diluted SAIRENJI  ET  AL.  1099 
antibody for 30 min. After being washed in PBS, the slides were mixed with the FITC- 
conjugated anti-human or anti-mouse IgG at 37 °C for 30 min. The slides were washed 
in PBS, mounted in 1:1  glycerol/PBS, and examined with a fluorescence microscope. 
Virus  Production.  P3HR-1  EBV  was  prepared  from  supernatants  of  P3HR-1  cell 
cultures after 14 d at 33°C (26). The supernatants were centrifuged at 900 g for 20 min 
to remove  cellular debris,  then  centrifuged again at  26,000  g  for  90  min.  The  virus- 
containing pellets were resuspended in medium at a  100-fold concentration relative to 
the original culture medium. The concentrated virus suspension was filtered through a 
membrane filter (0.45 t~M pore size) and stored in aliquots at -70°C.  The virus titer of 
this preparation was 5 ×  106 early antigen inducing units (EAIU)/ml (27). 
Assay of Viral Infectivity.  Infectious virus was assayed by viral induction of EA.  Raji 
cells were mixed with virus suspensions to give a final concentration of 106 cells/ml, then 
incubated at 37 °C for 90 min. After washing, the cells were suspended in fresh medium 
and incubated at 37 °C in a 5% COe incubator for 2 d. Infectivity of virus was determined 
by analysis for EAIU, where EAIU/ml =  (number of target Raji celis/ml) x  (fraction of 
EA  + cells)/(reciprocai dilution of the virus test solution) (27). For assay of cell-associated 
virus, pelleted ceils were washed and resuspended in fresh medium, sonicated for 60 s in 
an ice bath, and freed of debris by centrifugation at 900 g  for 10 min. The supernatant 
was assayed for virus. 
Neutralization  Assay.  The  neutralization assay quantitated  the  abrogation  of virus- 
induced EA expression (10, 28). Mixtures of 0.2 ml of virus suspension (diluted 1:5) and 
0.2 ml of heat-inactivated antibody dilutions were incubated overnight at 4°C.  Raji ceils 
(0.1  mi at  107 cells/ml) were then exposed for 90  min at 37°C  to such virus-antibody 
mixtures or to a  virus-medium mixture, then washed and resuspended at  106 cells/ml. 
For the assay of C-dependent neutralizing antibody, 0.05 ml of a freshly frozen seroneg- 
ative human serum (serum 60, in a  1:2 dilution, as a source of C) was added to 0.4 ml of 
the virus-serum mixture (after incubation overnight at 4°C) for a  60 min incubation at 
37°C.  RPMI  1640  with  25  mM  Hepes  was  used  as  a  diluent  of either  C  or  virus 
suspensions.  In order to avoid lysis of target Raji cells by cell-induced activation of the 
properdin pathway  (29),  0.05  ml  of  100  mM  EDTA  (final concentration  I0  raM) was 
added to the mixtures and incubated at 37°C  for  10 min before addition of Raji cells. 
The infected cultures were incubated at 37 ° C for 2 d. Acetone-fixed smears were prepared 
for the immunofluorescence test of EA induction (25).  A  neutralization index (NI) was 
calculated according to the formula described by Pearson et al. (10): NI =  ([percent EA  + 
virus-medium mixture]  -  [percent  EA  ÷ virus-antibody mixture])/(percent EA  + virus- 
medium mixture). 
Determination  of MA Molecular Weight.  A  microsomal membrane pellet was prepared 
from 10 s [35S]methionine-labeled P3HR-1 cells, which were harvested 48 h after treatment 
with TPA and n-butyrate. The microsomal membrane pellet was resuspended in ice-cold 
1%  Triton  X-100  in  PBS  (2  ml), and  membrane  proteins were  solubilized by shaking 
gently for 30 min at 4°C.  Undissolved material was sedimented at 110,000 g for 1 h. The 
supernatant  was  incubated  with  50  ~1  of normal  rabbit  serum  overnight at  4°C,  and 
cleared with 0.2  ml of a  10%  suspension of formalin-fixed S.  aureus (Cowan strain), by 
incubation for  10 min at 4°C and sedimentation of the bacteria at  12,000 g  for 15 min. 
The cleared supernatant (divided into 100 #i aliquots) was used for immunoprecipitation 
with antibodies (50 ul of serum 86  [anti-MA, titer 1:1,280],  from a  chronic IM patient, 
or 5 ~1 of ascites) at 4 °C for 1 h. This was followed by addition of an S. aureus suspension 
(0.4  ml) for  10  min  at 4°C,  then  centrifugation PBS  washing, and  elution of antigen. 
Antigen elution  was  done  by resuspending the bacteria in  100  #1  of 4%  SDS in  6  M 
aqueous  urea, and  heating at  100°C  for  10  rain.  This preparation was centrifuged at 
12,000 g  for  15  min, and the supernatant was collected. 20 #1 of 60  mM dithiothreitoi 
(DTT) in Laemmli sample buffer were added to each supernatant for incubation at 37 °C 
for  10 min (30).  The DTT-reduced proteins were alkylated by the addition of 20 ttl of 
75 mM iodoacetamide. These samples and radiolabeled molecular weight standards were 
subjected to SDS-PAGE. Gels were autoradiographed. 1100  EBV  RELEASE  BLOCKED  BY  MONOCLONAL  ANTIBODY 
Results 
Development  of mAb against EBV MA.  Hybridoma fusions were obtained  by 
standard  methods  (23),  and  culture  supernatants  were  evaluated  by  ELISA, 
testing  for  binding  to  P3-T/B  microsomal  membranes  and  low  nonspecific 
binding to CEM (T cell line) microsomal  membranes.  Among  17 cultures that 
were  reactive  with  P3-T/B  but  not  CEM  microsomal  membranes,  7  showed 
membrane  immunofluorescence  (MIF)  specific  for  a  subset  of P3-T/B  cells. 
Among these, which were subcloned twice and transferred to ascites, was clone 
1B6,  which  is  the  subject of this  report.  The  ascitic preparation  of this  mAb 
showed (a) MIF on P3-T/B cells (Fig.  1A), detectable to a  1:320,000 dilution; 
(b) cytoplasmic immunofluorescence  (CIF) on acetone-fixed P3-T/B cells (Fig. 
1 B), detectable to a  1:160,000 dilution;  and (c) ELISA reactivity to a  1:2,560 
dilution on P3-T/B membranes, while it was unreactive to CEM membranes at 
a  dilution  of  1:40  (results  not  shown).  The  antibody  is  of IgG2a  isotype,  as 
determined by Ouchterlony gel diffusion tests. 
EBV Specificity of 1B6.  The correspondence  between MIF and  CIF patterns 
of 1  B6 and two standard anti-MA + sera was tested under various conditions of 
EBV antigen  induction  in  P3HR-1  cells. Both TPA and n-butyrate can, alone, 
induce EBV antigens (31, 32), and they can act synergistically (33). For compar- 
ison, VCA and MA were detected with EBV  + sera from healthy individuals (53 
and 70  1:20 dilution).  In each instance of control or activated cell populations, 
1B6 reactivity closely paralleled  that  demonstrated  with serum  53 (Fig.  2) and 
with a second control serum, 70 (not shown, being indistinguishable from serum 
53).  In  addition  to  these  studies  with  activated  P3HR-1  cells  that  had  been 
cultured  at  37°C,  levels  of  MA  and  VCA  were  assessed  in  33°C-passaged 
P3HR-1 ceils that spontaneously express EBV antigens (21, 26). Again, the  1  B6 
mAb reactivity paralleled MA and VCA expression, as detected with sera 53 and 
70.  1  B6 also showed MIF to subpopulations of cells of other EBV-producing cell 
lines: B95-8 (34), QIMR-WIL (35), and Jijoye (36) cells, indicating crossreaction 
to EBV MA expressed by other strains  of EBV.  The intensity of MIF staining 
was much less on those cells than on P3HR-1 cells. 
Effect of PAA on Expression  of MA.  The effect of PAA on EBV MA induction 
by n-butyrate or by n-butyrate and TPA was followed by 1  B6 or anti-MA + human 
serum  70  (Table  I).  n-Butyrate  or  n-butyrate  plus  TPA  clearly  induced  MA 
within  48  h  in  P3HR-1  cultures.  However,  the  addition  of PAA (200  ~g/ml) 
completely blocked the  induction  of the  1B6-defined  MA,  indicating  that  the 
target antigen was a late MA component. 
Molecular Mass of MA Recognized  by 1B6.  Immunoprecipitates formed by the 
reaction of 1  B6 antibody or EBV  + serum (86, from a  chronic IM patient)  with 
TPA plus n-butyrate-activated,  [35S]methionine-labeled P3HR-1 cells were ana- 
lyzed by SDS-PAGE (Fig.  3).  A  200  kD protein  was immunoprecipitated  with 
1B6 mAb and with human serum 86. 
Virus Neutralization.  The  1B6 antibody was tested for P3HR-1 EBV neutral- 
ization  in  the  presence and  absence of C  (Fig.  4).  Without  C,  no neutralizing 
activity (NI =  0) was observed at any mAb concentration,  from 1:160 to 1:10. A 
control EBV seropositive human  serum (53) demonstrated  neutralizing  activity 
in a  dose-dependent fashion.  With C,  the  level of neutralization  with the sero- FIGURE  1.  Reactivity of 1 B6 mAb with P3-T/B cells as MIF in unfixed cells (A) or as CIF in 
acetone-fixed cells (B). 
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FIGURE 2.  Reactivity of P3HR-1 cells  with an EBV-seropositive human serum, 53 (1:20) or 
1B6 mAb (1:160) by indirect immunofluorescence (m,  MIF; r'~, CIF).  P3HR-1  cells were 
cultured in various conditions: 37°C, at 37°C for 2 d; TPA, with TPA (20 ng/ml) at 37°C for 
2 d; n-butyrate, with n-butyrate (4 raM) at 37°C for 2 d; TPA and n-butyrate, with TPA (20 
ng/ml) and n-butyrate (4 raM) at 37°C for 2 d; 330C, at 33°C for 10 d. 
TABLE  I 
Effect of PAA on Expression of 1B6 Antibody-recognized MA 
Antibody 
Oh 
MA  + cells (%) 
48 h 
Without  With PAA 
PAA 
Control  70  1.0  3.1  0.3 
1 B6  0.9  1.7  0.1 
n-Butyrate  70  1.0  18.7  1.2 
1 B6  0.9  11.9  0.6 
n-Butyrate and TPA  70  1.0  56.3  4.2 
1B6  0.9  51.2  0.9 
P3HR-1 cells  were treated with n-butyrate (4 mM) alone, or together with TPA 
(20 ng/ml), and were cultured in medium with or without PAA (200 #.g/ml). 
The MA  ÷ cells were quantitated by MIF at 48 h using IB6 mAb or anti-MA  ÷ 
human serum, 70. 
positive serum increased. Neutralization with  1B6 was observed, with NI =  0.6 
at  1:10, and then a plateau ofNI  =  0.3 at 1:20-1:160 dilutions of mAb. A  slight 
neutralizing activity was observed until 1:640. 
Inhibition of EBV Release.  Having found that antibody against an MA inhibits 
expression of EA in EBV-superinfected Raji cells (37), and knowing that antibody 
against a  membrane-expressed influenza virus neuraminidase inhibits release of SAIRENJI  ET  AL.  1103 
FIGURE 3.  Iinmunoprecipitation of [sSS]methionine-labeled  cell extracts from P3-T/B cells, 
comparing  IB6 mAb and serum 86 from a patient with cbronic IM. NMS, normal mouse 
serum. MWS, molecular weight standards. 
influenza virus (38), we tested  1  B6 for its effect on expression of viral antigens 
and release of infectious virus in 33 °C cultured P3HR-1 cells. P3HR-1 cells were 
cultured  with  either  1B6  antibody  (1:100  and  1:1000),  or  in  control  ascites 
without  anti-EBV  antibodies  (also at  1:100  and  1:1000).  Cell  growth  and  the 
frequency ofVCA + cells were not affected by 1B6 (Fig. 5A). However, the titer 
of infectious  virus  in  culture  fluids  was  decreased  at  days  13  and  20  after 
cultivation  with  1B6  (Fig.  5C).  While  titers  of cell-associated  infectious  virus 
were unchanged or even enhanced at 13 and 20 d in cultures containing antibody 
(Fig.  5B),  the  titers  of infectious virus  were  10-fold  (or  more)  reduced  from 
those in the control culture fluids (Fig. 5 C). The effect of varying concentrations 1104  EBV  RELEASE BLOCKED BY  MONOCLONAL  ANTIBODY 
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FIGURE 4.  P3HR-1 EBV neutralization with 1B6 mAb (O) and with seropositive human 
serum 53 (O) was tested with or without the addition of complement from a seronegative 
healthy donor (60). 
of  1B6  on  EBV  in  culture  supernatant  was  tested  as a  function  of time after 
cultivation at 33 °C (Fig. 6). Inhibition of the virus' appearance in culture medium 
was dependent  upon  dose of 1B6  mAb,  and  on  the duration  of culture.  50% 
inhibition  of release of virus  into the  supernatant  was observed at  1B6  ascitic 
titers of 1:400,000,  1:100,000, and 1:6,400 on days 10, 16, and 20, respectively. 
The effect of 1  B6 antibody on virus release was also tested with TPA plus n- 
butyrate-activated P3HR-1  cells at  37°C  (Fig.  7).  P3HR-1  cells were cultured 
with TPA (20 ng/ml) and n-butyrate (4 raM) in medium containing either  1B6 
(1:1,000),  or  control  ascites  (1:1,000)  for  6  d.  The  culture  fluids  and  cell- 
associated  infectious virus  were assayed  by the  EAIU  assay.  In  these cultures, 
maximal  induction  of  EA  occurred  in  60%  of the  cells  at  day  2,  and  1B6 
antibody-recognized MA expression was seen in 35-50% of the cells at 2 and 3 
d  after incubation with TPA and n-butyrate (Fig.  7A).  Cell viability decreased 
to  50-60%  at  day  3.  1B6  inhibited  the  appearance  of virus  in  the  culture 
medium;  2.5  x  103-4.0  x  103  EAIU/ml  vs.  1.5  ×  104-6.0  ×  104 EAIU/ml at 
days  1-6 (Fig.  7 C).  Cell-associated virus increased in both control and treated 
cultures to day  3  (Fig.  7B).  After 3  d,  levels of cell-associated virus in control 
cultures decreased,  but not in the  1 B6 antibody-treated cultures.  Net levels of 
virus  production  in  cells  and  culture  fluids  of  antibody-treated  and  control 
cultures were comparable.  Thus, inhibition of virus release was found not only 
in  33°C-cultivated  P3HR-1  cells,  but  also  in  the  37°C-cultured  P3HR-1  cells 
that had been treated with TPA plus n-butyrate. 
Reversibility  of EBV Release-inhibition.  The  reversibility of the  inhibition  of 
release of EBV by  1B6 antibody was tested in  P3-T/8  cells (Fig.  8).  Such cells 
were  cultured  for  48  h  with  1B6  mAb,  or  with  control ascites  fluid  (each  at 
1:1,000  dilution).  The  ceils  were  washed  twice  and  suspended  at  8  X  106 1 0 7 
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FIGURE  5.  Effect of  1B6  mAb on  expression of VCA  ÷ cells and  production  of infectious 
virus in  P3HR-I  cells grown  at  33°C.  Growth  of ceils and  expression  of VCA  ÷ cells  (A). 
Infectious EBV titers in sonicated cells (B) and in culture supernatants (C) were determined. 
1 B6 mAb (©,  1 : 100; O,  1 : 1,000); control mouse ascites (A,  1 : 100; A,  1 : 1,000); medium only 
(D). 
2i0 
cells/ml  in  fresh  medium,  with  or  without  1B6  antibody.  When  cells  were 
resuspended in 1  B6 mAb, virus release was inhibited in both cultures pretreated 
with  1B6  mAb or control ascites fluid for 48 h.  However, release of virus was 
observed in parallel from both cultures resuspended without 1B6  mAb. In the 
initial samples of cultures resuspended in control ascites medium, 5 X 102 EAIU/ 
ml were observed in the supernatant of the ascites-pretreated control culture, 
and < 102 EAIU/mi were observed in supernatant of the 1B6-pretreated cultures. 
At 8 h, the control culture medium demonstrated threefold greater virus titers 
than did the culture medium from 1B6-pretreated cultures. 
Discussion 
In  this study we describe an  mAb against an  EBV-induced,  200  kD,  PAA- 
sensitive (late) MA that functions in the release of EBV.The EBV specificity of 
this determinant was demonstrated by MIF and CIF.  1B6  antibody reactivity 
paralleled human serum staining for VCA and MA in P3HR-1  cells cultured at 
37°C,  or  33°C, or in  37°C-cultured and TPA-,  n-butyrate-, or TPA plus n- 
butyrate-treated cells.  Other EBV-producing cells (B95-8, Jijoye, and QIMR- 1106  EBV  RELEASE  BLOCKED  BY  MONOCLONAL  ANTIBODY 
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F~G~RE  6.  Dose  response  of  1B6  effect  on  virus  release  inhibition.  P3HR-1  cells  were 
cultured in medium containing various concentrations of 1B6 (O,  1:1.6 x  103; O,  1:6.4 ×  10s; 
A,  1:2.5  X  104;  &,  1:1.0 X  10~; Fl,  1:4.0 X  105);  or m, control ascites (1:1,000) at 33°C, and 
assayed for infectious virus in culture fluids. 
WIL) expressed the recognized determinant, but not as abundantly as did P3HR- 
1.  Since  1B6 recognized a  membrane  antigen  specific to EBV-producing cells, 
its target antigen was thought to be an EBV MA. Since PAA inhibited expression 
of this MA, it was, furthermore,  a late MA, requiring the functioning of EBV- 
DNA polymerase for its expression.  The  antibody detected a  200  kD protein 
immunoprecipitated  from [~SS]methionine-labeled,  detergent-solubilized micro- 
somal membranes of TPA plus n-butyrate-treated  P3HR-1 cells. A molecule of 
similar  mass has already been defined by others  (13-16,  18) to be a  principal 
component of EBV MA. 
Some MA components (gp350,  gp220,  and  gp85) are incorporated  into the 
EBV  envelope and  are  targets  for  neutralizing  antibodies  (10,  39).  However, 
1  B6 antibody had no neutralizing  activity without C (Fig. 4), and did not block 
neutralizing  activity of seropositive human  sera (data not shown). This finding 
contrasts with the report (14,  18) of C-independent neutralization  of EBV with 
other anti-gp220 mAb. We have previously reported (28) the assay of C-depend- 
ent,  EBV-neutralizing  antibody  in  human  sera.  1B6  antibody  gave  a  unique 
pattern  of  neutralization  with  C.  Although  this  pattern  was  observed  with 
different preparations of virus and C, it might not truly represent susceptibility 
of a subset of virus to C-dependent neutralization  with  1B6.  It is, therefore, an 
object of further study. 
The  1  B6 antibody blocked release of EBV in culture fluids with two methods 
for the production of P3HR-1 virus, but did not inhibit synthesis of VCA or EA, 
or expression of intracellular infectious virus. Spontaneous release of virus from 
33°C  cultured  cells,  or  release  of virus  from  37°C  cultured,  TPA  plus  n- 
butyrate-activated  cells  was  blocked  by  cultivation  with  1B6.  In  the  33°C 
cultures, the titer of infectious virus in the culture medium dropped appreciably 100 
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at 13 d. Throughout this process, intracellular infectious virus was still produced, 
in greater even amounts inside the viable, but release-blocked P3HR-I cells.  In 
the case of TPA  plus n-butyrate-induced  virus production,  1 or 2  d  of culture 
of such cells with  1B6  was sufficient  to demonstrate  inhibition  of virus release 
into culture  medium.  Again,  intracellular  virus was abundant  in  these release- 
inhibited  cells.  The  effect of blocking virus release was exquisitely  sensitive to 
the mAb; 50% inhibition of the virus release was observed (Fig.  6) to a  dilution 
of 1:4 ×  105 at  10 d  or  1:105 at  16 d. 
This phenomenon ofanti-MA-inhibition of virus release has not been observed 
previously  with  clinical  sera,  probably  because  virus-neutralizing  antibodies 
masked the  effect.  That  is,  inhibition  of release of EBV  with  clinical  sera that 
also  contained  neutralizing  antibodies  was  not  observed because  any virus re- 
leased in such cultures would promptly have been neutralized.  Previous reports 
have shown inhibition of EBV release by anti-virus release factor (AVRF) present 
in  bovine serum  (26,  40) and  in  EBV  seronegative human  serum  (41).  AVRF 
neither  neutralized  infectivity of EBV,  nor inhibited  intracellular virus produc- 
tion at concentrations that inhibited the release of virus into culture fluids.  The 1108  EBV  RELEASE  BLOCKED  BY  MONOCLONAL  ANTIBODY 
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FIGURE  8.  Reversibility  of virus release-inhibition.  P3-T/B  cultures  treated  with  1B6  (0, 
1:1,000) or with control ascites (O,  1 : 1,000) for 48 h  were washed and resuspended in either 
fresh medium (  ) or 1B6 (1:1,000) containing medium (---). 
pattern  of virus release inhibition  by AVRF was thus comparable to that  seen 
with  1B6 antibody, and might involve common mechanisms. 
Since"inhibition of virus release by 1  B6 is promptly reversed upon removal of 
the antibody, we can suggest that the blocking of virus release might occur at a 
final  stage in  virus release after viral envelopment.  We should now be able to 
study the mechanism of virus release in more detail, using 1B6. Since it appears 
that only some mAb against gp250/200 exhibit virus neutralization (14,  18), we 
can  also test  whether  other  nonneutralizing  anti-gp250/200  mAb also inhibit 
virus  release.  In  the  face of disparity  between virus  neutralization  and  virus 
release-inhibition  by various mAb directed against the 250/200 kD protein of 
MA,  one could hypothesize either  that  two gp250/200  molecules mediate  the 
respective functions, or that different functional domains exist on one molecule. 
While  we  have  characterized  anti-MA-mediated  inhibition  of EBV  release 
only in  the  P3HR-1  strain,  this  process will  probably be generalized  to other 
strains of EBV.  Thorley-Lawson and Geilinger (18) have demonstrated shared 
MA epitopes between gp350, the major glycoprotein in B95-8, and gp220,  the 
major glycoprotein in P3HR-1, suggesting that these molecules are structurally 
related.  We have demonstrated  immunofluorescence crossreactivity of the  1B6 
antibody-recognized  determinant  of p200  MA  on  P3HR-1  and  epitopes  ex- 
pressed on B95-8, Jijoye, and  QIMR-WIL cells. It will be important  to charac- 
terize  the  generality  of this  EBV  release-suppression  phenomenon  to  other 
laboratory and  wild  type strains  of EBV.  Also,  since  patients  raise  antibodies SAIRENJI ET  AL.  1109 
against  p200  (Fig.  3),  one  can  also  expect  to  quantitate  patients'  antibodies 
against the epitope identified by  1B6  antibody. For example, one could deter- 
mine, in the course of IM, the appearance of the antibodies that inhibit EBV 
release or  neutralize EBV  relative to antibodies against other  EBV  antigens. 
Whether such EBV release-inhibiting antibodies occur in chronic or recurrent 
EBV infections, or whether they are deficient in XLP, could also be explored. 
We will seek to elucidate the detailed mechanism of inhibition of virus release 
and the clinical significance of this process. 
Summary 
In  raising  routine  hybridoma antibodies against  Epstein-Barr  virus  (EBV)- 
induced membrane  antigens (MA),  we  found one  antibody that  blocked  the 
release of infectious EBV from cultured P3HR-1 ceils. This monoclonM antibody 
(mAb) recognized a  200 kD, phosphonoacetic acid-sensitive (late) MA, and did 
not directly neutralize virus without complement. When this mAb was added to 
33°C-cultured,  spontaneously EBV-producing  P3HR-1  cells,  the  intracellular 
expression of viral capsid antigen and infectious virus was not inhibited, but the 
appearance of infectious virus in the culture medium was significantly reduced. 
The duration of this suppression was dependent upon the concentration of the 
mAb, an effect being observed to a 1:4 ×  105 titer of  the ascites mAb preparation. 
A  more acute effect of suppression of EBV release was  observed in a  second 
model of 12-0-tetradecanoyl phorbol- 13-acetate and n-butyrate induction of EBV 
in 37°C-cultured P3HR-1  cells. Again, intracellular infectious virus production 
was not inhibited, but the level of infectious virus in the culture medium was 
significantly reduced as early as  1 and 2 d  of culture with antibody. This effect 
was reversed within  31  h  after replacement of mAb-containing medium with 
fresh medium. This description of antibody-mediated inhibition of EBV release 
might lead to the characterization of another form of immune defense for the 
control of EBV infections. 
We gratefully acknowledge the"  excellent secretarial assistance of Ms. Marion Bonin and 
Ms. Lena DeSantis in the preparation of this manuscript. 
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